Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Twice or Three Times Daily in Patients With Acute Ankle Sprain
- Conditions
- Grade I/II Ankle Sprain
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- Novartis
- Target Recruit Count
- 242
- Registration Number
- NCT00955513
- Locations
- 🇩🇪
Novartis Investigative Site, Munchen, Germany
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 716
- Registration Number
- NCT00948766
- Locations
- 🇺🇸
Clinical Research Advantage Inc./Neurological. Physicians of Arizona, Inc, Tempe, Arizona, United States
🇺🇸Northwest Neuro Specialist, PLLC, Tucson, Arizona, United States
🇺🇸IHS Research Center Inc., Conway, Arkansas, United States
Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010
- Conditions
- Seasonal Influenza
- Interventions
- Biological: inactivated split influenza vaccine
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 126
- Registration Number
- NCT00945841
- Locations
- 🇩🇪
Site 2, Giessen, Germany
🇩🇪Site 1, Herborn, Germany
🇩🇪Site 3, Marburg, Germany
Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: Aliskiren/Amlodipine
- First Posted Date
- 2009-07-21
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 412
- Registration Number
- NCT00942994
- Locations
- 🇺🇸
K and S Research Services, Little Rock, Arkansas, United States
🇺🇸Well Pharma Medical Research, South Miami, Florida, United States
🇺🇸Hyde Park Health Associates, Mattapan, Massachusetts, United States
Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension
- Conditions
- Stage 2 Systolic Hypertension
- Interventions
- Drug: valsartan, amlodipine, HCTZDrug: Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 488
- Registration Number
- NCT00931710
- Locations
- 🇺🇸
sites in USA, East Hanover, New Jersey, United States
1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1066
- Registration Number
- NCT00929110
- Locations
- 🇷🇺
Novartis Investigative Site, Yaroslavl, Russian Federation
🇳🇿Novartis Investigator Site, Wellington, New Zealand
🇺🇸Novartis Investigative site, Charlotte, North Carolina, United States
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1143
- Registration Number
- NCT00927394
- Locations
- 🇺🇸
Investigative Site, Philadelphia, Pennsylvania, United States
Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 20
- Registration Number
- NCT00925730
- Locations
- 🇩🇪
Novartis Investigative Site, Frankfurt am Main, Germany
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- Novartis
- Target Recruit Count
- 556
- Registration Number
- NCT00900146
- Locations
- 🇺🇸
Anasazi Internal Medicine, Phoenix, Arizona, United States
🇺🇸Whittier Institute of Diabetes, La Jolla, California, United States
🇷🇴Novartis Investigative Site, Bucuresti, Romania
Efficacy and Safety of BGG492 in the Treatment of Migraine
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 75
- Registration Number
- NCT00892203
- Locations
- 🇺🇸
California Clinical Trials, 1560 Chevy Chase Drive, Suite 140, Glendale, California, United States
🇺🇸California Clinical Trials, 15625 Lakewood Boulevard, Paramount, California, United States
🇪🇸Novartis Investigative Site, Barcelona, Spain